Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd has experienced a favorable increase in its equipment utilization rate by over 50% following strategic investments, highlighting the operational efficiency of its Deep Transcranial Magnetic Stimulation (Deep TMS) platform. As the company moves towards a pay-per-use model and benefits from an expanding prescriber base, particularly among neurologists, there is strong potential for accelerated revenue growth in the coming years. Additionally, the company's clinic infrastructure is being increasingly optimized to offer complementary treatments, positioning BrainsWay favorably within the evolving mental health treatment landscape.

Bears say

BrainsWay Ltd faces several significant risks that contribute to a negative outlook on its stock performance. Key concerns include the slower-than-expected adoption of its Deep TMS systems, alongside challenges in expanding reimbursements and market access, which are critical for revenue generation. Additionally, the company's difficulties in advancing other clinical indications and the potential for long-term dilution further exacerbate the financial uncertainties surrounding its operations.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.